279 related articles for article (PubMed ID: 30174236)
1. [MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer].
Baldacci S; Kherrouche Z; Descarpentries C; Wislez M; Dansin E; Furlan A; Tulasne D; Cortot AB
Rev Mal Respir; 2018 Oct; 35(8):796-812. PubMed ID: 30174236
[TBL] [Abstract][Full Text] [Related]
2. Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations.
Huang C; Zou Q; Liu H; Qiu B; Li Q; Lin Y; Liang Y
Curr Treat Options Oncol; 2020 Apr; 21(4):33. PubMed ID: 32306194
[TBL] [Abstract][Full Text] [Related]
3. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.
Reungwetwattana T; Liang Y; Zhu V; Ou SI
Lung Cancer; 2017 Jan; 103():27-37. PubMed ID: 28024693
[TBL] [Abstract][Full Text] [Related]
4. MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life.
Drilon A
Clin Cancer Res; 2016 Jun; 22(12):2832-4. PubMed ID: 27009743
[TBL] [Abstract][Full Text] [Related]
5. Going After
Cancer Discov; 2019 Aug; 9(8):OF9. PubMed ID: 31209157
[TBL] [Abstract][Full Text] [Related]
6. [MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer].
Yin L; Lu Y
Zhongguo Fei Ai Za Zhi; 2018 Jul; 21(7):553-559. PubMed ID: 30037377
[TBL] [Abstract][Full Text] [Related]
7. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.
Heist RS; Sequist LV; Borger D; Gainor JF; Arellano RS; Le LP; Dias-Santagata D; Clark JW; Engelman JA; Shaw AT; Iafrate AJ
J Thorac Oncol; 2016 Aug; 11(8):1242-1245. PubMed ID: 27343442
[TBL] [Abstract][Full Text] [Related]
8. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
Wu YL; Smit EF; Bauer TM
Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
[TBL] [Abstract][Full Text] [Related]
9. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
[TBL] [Abstract][Full Text] [Related]
10. MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis.
Tong JH; Yeung SF; Chan AW; Chung LY; Chau SL; Lung RW; Tong CY; Chow C; Tin EK; Yu YH; Li H; Pan Y; Chak WP; Ng CS; Mok TS; To KF
Clin Cancer Res; 2016 Jun; 22(12):3048-56. PubMed ID: 26847053
[TBL] [Abstract][Full Text] [Related]
11. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
Awad MM; Oxnard GR; Jackman DM; Savukoski DO; Hall D; Shivdasani P; Heng JC; Dahlberg SE; Jänne PA; Verma S; Christensen J; Hammerman PS; Sholl LM
J Clin Oncol; 2016 Mar; 34(7):721-30. PubMed ID: 26729443
[TBL] [Abstract][Full Text] [Related]
12. MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer.
Zheng D; Wang R; Ye T; Yu S; Hu H; Shen X; Li Y; Ji H; Sun Y; Chen H
Oncotarget; 2016 Jul; 7(27):41691-41702. PubMed ID: 27223439
[TBL] [Abstract][Full Text] [Related]
13. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
[TBL] [Abstract][Full Text] [Related]
14. [Expert Consensus on Targeted Therapy of NSCLC with MET Exon 14
Skipping Mutation].
Editorial Office of Chinese Journal of Lung Cancer
Zhongguo Fei Ai Za Zhi; 2023 Jun; 26(6):416-428. PubMed ID: 37488079
[TBL] [Abstract][Full Text] [Related]
15. Crizotinib in MET Exon 14-Mutated or MET-Amplified in Advanced Disease Non-Small Cell Lung Cancer: A Retrospective, Single Institution Experience.
Shalata W; Yakobson A; Weissmann S; Oscar E; Iraqi M; Kian W; Peled N; Agbarya A
Oncology; 2022; 100(9):467-474. PubMed ID: 35679833
[No Abstract] [Full Text] [Related]
16. The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping.
Salgia R; Sattler M; Scheele J; Stroh C; Felip E
Cancer Treat Rev; 2020 Jul; 87():102022. PubMed ID: 32334240
[TBL] [Abstract][Full Text] [Related]
17. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.
Paik PK; Drilon A; Fan PD; Yu H; Rekhtman N; Ginsberg MS; Borsu L; Schultz N; Berger MF; Rudin CM; Ladanyi M
Cancer Discov; 2015 Aug; 5(8):842-9. PubMed ID: 25971939
[TBL] [Abstract][Full Text] [Related]
18. Tepotinib in Non-Small-Cell Lung Cancer with
Paik PK; Felip E; Veillon R; Sakai H; Cortot AB; Garassino MC; Mazieres J; Viteri S; Senellart H; Van Meerbeeck J; Raskin J; Reinmuth N; Conte P; Kowalski D; Cho BC; Patel JD; Horn L; Griesinger F; Han JY; Kim YC; Chang GC; Tsai CL; Yang JC; Chen YM; Smit EF; van der Wekken AJ; Kato T; Juraeva D; Stroh C; Bruns R; Straub J; Johne A; Scheele J; Heymach JV; Le X
N Engl J Med; 2020 Sep; 383(10):931-943. PubMed ID: 32469185
[TBL] [Abstract][Full Text] [Related]
19. Capmatinib in
Wolf J; Seto T; Han JY; Reguart N; Garon EB; Groen HJM; Tan DSW; Hida T; de Jonge M; Orlov SV; Smit EF; Souquet PJ; Vansteenkiste J; Hochmair M; Felip E; Nishio M; Thomas M; Ohashi K; Toyozawa R; Overbeck TR; de Marinis F; Kim TM; Laack E; Robeva A; Le Mouhaer S; Waldron-Lynch M; Sankaran B; Balbin OA; Cui X; Giovannini M; Akimov M; Heist RS;
N Engl J Med; 2020 Sep; 383(10):944-957. PubMed ID: 32877583
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis.
Vuong HG; Ho ATN; Altibi AMA; Nakazawa T; Katoh R; Kondo T
Lung Cancer; 2018 Sep; 123():76-82. PubMed ID: 30089599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
